Document is current
Any future updates will be listed below
-
Authors
Cuesta-Gomez, Nerea https://orcid.org/0000-0002-1976-6298
Verhoeff, Kevin https://orcid.org/0000-0003-3110-5238
Dadheech, Nidheesh https://orcid.org/0000-0002-7155-0486
Dang, Tiffany https://orcid.org/0009-0002-9108-3886
Jasra, Ila Tewari
de Leon, Mario Bermudez https://orcid.org/0000-0002-0993-2969
Pawlick, Rena https://orcid.org/0000-0002-0391-7901
Marfil-Garza, Braulio https://orcid.org/0000-0002-7224-2127
Anwar, Perveen
Razavy, Haide
Zapata-Morin, Patricio Adrián https://orcid.org/0000-0003-1851-2293
Jickling, Glen
Thiesen, Aducio https://orcid.org/0000-0001-6836-8619
O’Gorman, Doug https://orcid.org/0000-0001-5304-4769
Kallos, Michael S. https://orcid.org/0000-0002-1480-8022
Shapiro, A. M. James https://orcid.org/0000-0002-6215-0990
-
Funding
Funding for this research was provided by:
Canada Research Chairs
Juvenile Diabetes Research Foundation Canada
Diabetes Canada
Canadian Donation and Transplant Research Program
Diabetes Research Institute Foundation of Canada
Alberta Diabetes Institute
Stem Cell Network
Patronato del Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Fundacion para la Salud y la Educacion Dr. Salvador Zubirán
CHRISTUS Excellence and Innovation Center
- License Information
-
More Information
Article History
Received: 24 October 2022
Accepted: 18 May 2023
First Online: 6 June 2023
Declarations
:
: All procedures and protocols have been reviewed and approved by the Stem Cell Oversight Committee (SCOC), Canada, and the University of Alberta Institutional Health Research Ethics Board (PRO00084032). Ethics has been reviewed under the title “On-going review of islet and progenitor cell transplant patients at the University of Alberta” and approved by the Health Research Ethics Board Biomedical review committee on February 2, 2014 with most recent renewal approved on December 20, 2022. This study adhered to the Declaration of Helsinki. All animal protocols were conducted in accordance with the Canadian Council on Animal Care Guidelines and Policies with approval from the Animal Care and Use Committee (Health Sciences) for the University of Alberta (included within the above ethics application).
: Patients recruited in this study as blood sample donors provided written consent for use of tissue, cell reprogramming, and result disclosure.
: AMJS serves as a consultant to ViaCyte Inc., Vertex Inc., Betalin Ltd., Hemostemix Inc. and Aspect Biosystems Ltd. No conflict of interest exists for all other co-authors.
